Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Renal cell carcinoma Stories

2009-11-09 06:00:00

Article published in December 2009 issue of the Journal of Urology QUEBEC CITY, Nov. 9 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced publication of a scientific article in the renowned Journal of Urology, supporting the development of the Company's PI3K/Akt pathway inhibitor oral compound, perifosine, for the treatment of cancer. The article outlines the...

2009-11-03 09:44:00

The NCCN Guidelines for Kidney Cancer have been updated to incorporate the recently approved therapy pazopanib as a treatment option for patients with advanced renal cell carcinoma. In conjunction with this update, NCCN presents a series of free webinars scheduled for the week of November 9, 2009, hosted by an NCCN Guidelines Panel Member to review the information that supported modification of the NCCN Guidelines. FORT WASHINGTON, Pa., Nov. 3 /PRNewswire-USNewswire/ -- Following the...

2009-10-19 19:17:00

PHILADELPHIA, Oct. 19 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved VOTRIENT(TM) (pazopanib) to treat patients with advanced renal cell carcinoma (RCC), a form of kidney cancer. Approximately 57,700 people in the U.S. will be diagnosed with kidney cancer this year, and 13,000 people will die from this disease. "RCC is the most common malignancy of the kidney and is highly resistant to chemotherapy,"...

2009-10-19 17:30:00

SILVER SPRING, Md., Oct. 19 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive. Votrient is intended for people with advanced renal cell carcinoma, a type of kidney cancer...

2009-10-05 15:48:00

PHILADELPHIA, Oct. 5 /PRNewswire/ -- GlaxoSmithKline [NYSE: GSK] today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC. "Kidney cancer is a...

2009-09-30 01:00:00

WAYNE, N.J. and EMERYVILLE, Calif., Sept. 30 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from a randomized, placebo-controlled Phase 2 trial sponsored by Northwestern University. The study, which evaluated Nexavar® (sorafenib) tablets in combination with the chemotherapeutic agent, paclitaxel, in patients with locally advanced or metastatic HER-2 negative breast cancer, demonstrated a...

2009-09-29 07:05:00

Perifosine Continues to Demonstrate Impressive Efficacy, Safety and Tolerability in Metastatic Renal Cell Carcinoma Patients who Progressed after Failing Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor QUEBEC CITY, Sept. 29 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX),...

2009-09-29 07:00:00

NEW YORK, Sept. 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced updated clinical results from a Phase 2 study of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single-agent treatment for advanced metastatic renal cell carcinoma (RCC). Dr. Thomas E. Hutson, Director of the Genitourinary Oncology Program at Baylor-Sammons Cancer Center in Dallas, Texas, presented the data on Saturday, September 26th, in an oral...

2009-09-25 11:57:00

FRIMLEY, England, September 25 /PRNewswire/ -- - This Press Release is Intended for Consumer Media Only - Afinitor More Than Doubles the Median Time Without Tumour Growth and Reduces the Risk of Disease Worsening or Death by 67% Compared With Placebo (2) - Patients With Advanced Kidney Cancer Have Limited Options Once Tumours Progress After First Line Standard Therapy(3) - Recently Published UK Expert Clinical Consensus Recommend Afinitor as Second-Line...

2009-09-22 02:05:00

BERLIN, Sept. 22 /PRNewswire/ -- Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC). These data were presented in an oral session at the joint 15th Congress of the European CanCer Organisation and 34th Congress of the European Society...